These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 1588038)

  • 21. Toxic oil syndrome, Spain: effect of oleoylanilide on the release of polysaturated fatty acids and lipid peroxidation in rats.
    Suarez A; Viloria MD; Garcia-Barreno P; Municio AM
    Arch Environ Contam Toxicol; 1985 Mar; 14(2):131-6. PubMed ID: 3920977
    [No Abstract]   [Full Text] [Related]  

  • 22. The genotype determines the B cell response in mercury-treated mice.
    Johansson U; Hansson-Georgiadis H; Hultman P
    Int Arch Allergy Immunol; 1998 Aug; 116(4):295-305. PubMed ID: 9693280
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The toxic oil syndrome: an example of an exogenously induced autoimmune reaction. Toxic oil syndrome.
    Bell SA
    Mol Biol Rep; 1996; 23(3-4):261-3. PubMed ID: 9112238
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sjögren's syndrome in the NOD mouse model is an interleukin-4 time-dependent, antibody isotype-specific autoimmune disease.
    Gao J; Killedar S; Cornelius JG; Nguyen C; Cha S; Peck AB
    J Autoimmun; 2006 Mar; 26(2):90-103. PubMed ID: 16413168
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunotoxic response of oleic acid anilide and its hydrolysis products in female MRL (+/+) mice.
    Cai P; Khan MF; Kaphalia BS; Ansari GA
    J Immunotoxicol; 2005 Oct; 2(4):231-6. PubMed ID: 18958679
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytokine mRNA expression in lung tissue from toxic oil syndrome patients: a TH2 immunological mechanism.
    del Pozo V; de Andrés B; Gallardo S; Cárdaba B; de Arruda-Chaves E; Cortegano MI; Jurado A; Palomino P; Oliva H; Aguilera B; Posada M; Lahoz C
    Toxicology; 1997 Mar; 118(1):61-70. PubMed ID: 9074654
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chemical correlates of pathogenicity of oils related to the toxic oil syndrome epidemic in Spain.
    Kilbourne EM; Bernert JT; Posada de la Paz M; Hill RH; Abaitua Borda I; Kilbourne BW; Zack MM
    Am J Epidemiol; 1988 Jun; 127(6):1210-27. PubMed ID: 3369420
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Autoimmunity caused by disruption of central T cell tolerance. A murine model of drug-induced lupus.
    Kretz-Rommel A; Duncan SR; Rubin RL
    J Clin Invest; 1997 Apr; 99(8):1888-96. PubMed ID: 9109433
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oleoylanilide, a possible causative agent of toxic oil syndrome, interferes with the cytoskeleton in a neuronal cell line.
    Martínez JL; Behrens MM; Moratilla C; Renart J
    Neurotoxicol Teratol; 1997; 19(2):147-50. PubMed ID: 9136131
    [TBL] [Abstract][Full Text] [Related]  

  • 30. B cell apoptosis accelerates the onset of murine lupus.
    Trébéden-Nègre H; Weill B; Fournier C; Batteux F
    Eur J Immunol; 2003 Jun; 33(6):1603-12. PubMed ID: 12778478
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Toxic oil syndrome: the perspective after 20 years.
    Posada de la Paz M; Philen RM; Borda AI
    Epidemiol Rev; 2001; 23(2):231-47. PubMed ID: 12192735
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 1-Phenyl-5-vinyl-2-imidazolidinethione, a proposed causative agent of Spanish toxic oil syndrome: synthesis, and identification in one of a group of case-associated oil samples.
    Kammüller ME; Verhaar HJ; Versluis C; Terlouw JK; Brandsma L; Penninks AH; Seinen W
    Food Chem Toxicol; 1988 Feb; 26(2):119-27. PubMed ID: 3366411
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dextran-conjugated anti-IgD antibodies inhibit T cell-mediated IgE production but augment the synthesis of IgM and IgG.
    Peçanha LM; Yamaguchi H; Lees A; Noelle RJ; Mond JJ; Snapper CM
    J Immunol; 1993 Mar; 150(6):2160-8. PubMed ID: 7680684
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Autoimmunization in murine graft-vs-host disease. I. Selective production of antibodies to histones and DNA.
    Portanova JP; Claman HN; Kotzin BL
    J Immunol; 1985 Dec; 135(6):3850-6. PubMed ID: 3877758
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Localized scleroderma is an autoimmune disorder.
    Takehara K; Sato S
    Rheumatology (Oxford); 2005 Mar; 44(3):274-9. PubMed ID: 15561734
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Autoantibodies to cryptic epitopes of C-reactive protein and other acute phase proteins in the toxic oil syndrome.
    Bell SA; Du Clos TW; Khursigara G; Picazo JJ; Rubin RL
    J Autoimmun; 1995 Apr; 8(2):293-303. PubMed ID: 7542004
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Investigating the onset of autoimmunity in A.SW mice following treatment with 'toxic oils'.
    Weatherill AR; Stang BV; O'Hara K; Koller LD; Hall JA
    Toxicol Lett; 2003 Jan; 136(3):205-16. PubMed ID: 12505274
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Skin manifestations of toxic syndrome due to denatured rapeseed oil].
    Fonseca E
    Actas Dermosifiliogr; 2009 Dec; 100(10):857-60. PubMed ID: 20038361
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mass spectrometric identification of N-phenyllinoleamide metabolites in mouse peritoneal macrophages.
    Bioque G; Abián J; Bulbena O; Roselló-Catafau J; Gelpí E
    Rapid Commun Mass Spectrom; 1995; 9(9):753-60. PubMed ID: 7655069
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Toxic oil syndrome: genetic restriction and immunomodulatory effects due to adulterated oils in a model of HLA transgenic mice.
    Gallardo S; Cárdaba B; Posada M; del Pozo V; Messeguer A; David CS; Lahoz C
    Toxicol Lett; 2005 Nov; 159(2):173-81. PubMed ID: 15979827
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.